NCT06948409

NMBA Reversal and Postoperative Urinary Retention

The Choice of Neuromuscular Blockade Reversal Agent and Its Effects on Postoperative Urinary Retention: A Retrospective Cohort Study

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 70,000 (estimated)
• Sponsor: Beth Israel Deaconess Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

In this single-center retrospective cohort study of adult patients who underwent surgery under general anesthesia at Beth Israel Deaconess Medical Center between September 2016 and January 2024, the association between the choice of neuromuscular blocking agent (NMBA) reversal strategy, comparing sugammadex with neostigmine (combined with a muscarinic antagonist), and postoperative urinary retention (POUR) will be evaluated. In secondary analyses, the effects of NMBA reversal strategy and POUR on costs of care and unplanned hospital visits will be analyzed.

Conditions

• Neuromuscular Blocking Agents
• Urinary Retention After Procedure
• Urinary Retention Postoperative
• Neuromuscular Blockade Reversal Agent
• Neuromuscular Blockade
• Costs
• Atropine
• Sugammadex
• Glycopyrrolate
• Neostigmine
• Anesthesia

Interventions

Type	Name	Description
DRUG	Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])	The use of sugammadex or neostigmine (in co-administration with muscarinic antagonist) will be compared. The muscarinic antagonists that will be considered are atropine and glycopyrrolate.

Timeline

• Start date: 2025-06-08
• Primary completion: 2025-08-31
• Completion: 2026-06-01
• First posted: 2025-04-29
• Last updated: 2026-01-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study